

# Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein

Catalog No.: RP00282 Recombinant

# **Sequence Information**

**Species Gene ID Swiss Prot** Human 8795 014763-1

**Tags** C-His

**Synonyms** 

CD262;DR5;KILLER;KILLER/DR5;TRAIL-R2;TRAILR2;TRICK2;TRICK2A;TRICK2B;TR ICKB;ZTNFR9;TNFRSF10B

# **Product Information**

**Source** Purification HEK293 cells ≥ 90 % as

determined by SDS-

PAGE.

Calculated MW Observed MW

15.13 kDa 17 kDa

#### **Endotoxin**

 $< 0.1 \; \text{EU/}\mu\text{g}$  of the protein by LAL method.

#### **Formulation**

Lyophilized from a 0.22 µm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.

#### Reconstitution

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

# **Contact**

6	400-999-6126
$\bowtie$	cn.market@abclonal.com.cn
•	www.abclonal.com.cn

# **Background**

This protein is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

## **Basic Information**

## **Description**

Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Ile 56 - Glu 182) of human DR5 (Accession  $\#NP_003833.3$ ) fused with a 6×His tag at the C-terminus.

#### **Bio-Activity**

1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human TRAIL at 2  $\mu g/mL$  (100  $\mu L/well$ ) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.|2.Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED $_{50}$  for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.|3.Measured by its binding ability in a functional ELISA.Immobilized Human TRAIL / TNFSF10 Protein at  $2\mu g/mL$  (100  $\mu L/well$ ) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.


## Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.


After reconstitution, the protein solution is stable at -20  $^{\circ}$ C for 3 months, at 2-8  $^{\circ}$ C for up to 1 week.

Avoid repeated freeze/thaw cycles.


# **Validation Data**




Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Immobilized Recombinant Human TRAIL at  $2\mu g/mL$  (100  $\mu L/well)$  can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.



Recombinant Human TNFRSF10B inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED $_{50}$  for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.



Immobilized Human TRAIL / TNFSF10 Protein at 2 $\mu$ g/mL (100  $\mu$ L/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.